register

News & Trends - Pharmaceuticals

Disruption to medicines supply chain leads to growing concerns

Health Industry Hub | March 9, 2020 |

The Pharmacy Guild of Australia has warned that panic buying of medicines is unnecessary and may have unintended consequences for Australian patients.

The National President of the Pharmacy Guild, George Tambassis, said pharmacists had professional and legal responsibilities to ensure appropriate and safe supply of prescription medicines, and dispensing multiple repeats without good reason was inadvisable and outside the guidelines published by the Pharmacy Board of Australia.

The TGA is utilising information it has about Chinese manufacturers and is having active discussions with Australian medicine sponsors, wholesalers and pharmacists to determine any potential future impact to medicine supply.

Australia imports over 90% of medicines and is at the end of a very long global supply chain, making the nation vulnerable to supply chain disruptions.

China not only manufactures drugs but makes many of the active pharmaceutical ingredients (APIs) used by drug manufacturers in other countries, such as the United States, from which Australia imports 20% of its pharmaceuticals.

Enhance corporate branding and boost thought leadership to attract and retain quality employees. How does your company culture and digital footprint measure up in the Australian Pharma industry? Get the benchmark report by contacting us.

As of last week, the Indian government restricted the exports of 26 medicines and pharmaceutical ingredients, including paracetamol.

Mr Tambassis was responding to numerous anecdotal reports of consumers trying to “stock-up” on prescription medicines because of fears the onset of COVID-19 might lead to medicine shortages in Australia. Wholesalers have also reported higher than usual demand for prescription and over-the-counter medicines.

There is currently no recommendation from the Chief Medical Officer, Departments of Health or any other public health authority of the need for patients to stockpile.

“The Pharmacy Guild is not aware of any medicine which is currently unavailable or in short supply in Australia specifically because of COVID-19,” Mr Tambassis said.

“Medication shortages and out of stocks have been part of the pharmacy landscape for the last couple of years threatening continuity of supply for patients and requiring numerous brand substitution changes for some patients, but these issues pre-dated and are entirely unrelated to coronavirus.

“Paradoxically, if panic buying does take hold for medicines and other products, shortages may well arise – and we certainly hope this can be avoided,” he said.

Suppliers & Service Providers: Enhance business visibility, differentiate your brand and maximise your reach. Discover our unique digital media solutions with superior open rates and click through rates (CTRs).


News & Trends - Pharmaceuticals

Heart week: Uniting patient and cardiologist voices to shape patient outcomes

Heart Week: Uniting patient and cardiologist voices in shaping a new future for patient outcomes

Health Industry Hub | May 6, 2024 |

Coinciding with the start of the Heart Week (9 – 12 May), Professor Gemma Figtree, Interventional Cardiologist and Immediate Past […]

More


News & Trends - MedTech & Diagnostics

‘It’s a marathon not a sprint’: Industry leaders chart next steps in medtech’s sustainability journey

Health Industry Hub | May 6, 2024 |

Ahead of World Environment Day in June, Jane Crowe, Managing Director of Cardinal Health Australia and New Zealand and Pravin […]

More


News & Trends - Pharmaceuticals

Vaccination accounts for almost half of mortality decline in infants

Vaccination accounts for almost half of mortality decline in infants

Health Industry Hub | May 6, 2024 |

Pharma News: Researchers have mapped the impact of vaccines to mark the 50-year anniversary of the Expanded Programme on Immunisation […]

More


News & Trends - Pharmaceuticals

AbbVie, Pfizer and Bayer therapies to be considered at upcoming PBAC intracycle meeting

AbbVie, Pfizer and Bayer therapies to be considered at upcoming PBAC intracycle meeting

Health Industry Hub | May 6, 2024 |

Pharma News: Therapies from AbbVie, Pfizer and Bayer are due to be considered at the Pharmaceutical Benefits Advisory Committee (PBAC) […]

More


This content is copyright protected. Please subscribe to gain access.